Rare (occurring in <1% of patients) side effects include:
- heart problems,
- movement disorders,
- duodenal ulcer,
- facial edema (swelling),
- gastric ulcer,
- iincreased libido,
- pathological gambling,
- psychosis, /li>
- lung problems, and
- weight gain or loss.
GENERIC AVAILABLE: Yes
PREPARATIONS: Oral tablets: 0.5 mg
STORAGE: Tablets should be stored at room temperature, between 15 C to 30 C (59 F to 86 F).
DOSING: Cabergoline is better tolerated when administered with food.
For the treatment of hyperprolactinemia in adults: The recommended starting dose of cabergoline is 0.25 mg twice weekly. The dose is gradually increased usually by adding 0.25 mg per week at monthly intervals up to 1 mg twice weekly based on serum prolactin levels. Once a normal serum prolactin level is maintained for at least 6 months, cabergoline may be discontinued. Prolactin levels in these patients must be monitored to determine if restarting treatment is necessary.
DRUG INTERACTIONS: Cabergoline is related to the ergot alkaloids. The use of cabergoline with other ergot alkaloids is not recommended due to the increased risk for adverse events. Ergot alkaloids are commonly used to treat migraine headaches. Therefore, patients receiving treatment for migraine headaches should discuss treatment with cabergoline with their doctor or pharmacist before using cabergoline.
Cabergoline works by stimulating dopamine receptors in the brain. It should not be used with dopamine antagonists or blockers which might decrease or cancel out the beneficial effects of cabergoline. Examples of dopamine antagonists are phenothiazines, butyrophenones, thioxanthenes, and metoclopramide (Reglan).
Quick GuidePrescription Drug Abuse: Know The Warning Signs
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.